Benjamin Duncan

1.8k total citations · 1 hit paper
23 papers, 1.4k citations indexed

About

Benjamin Duncan is a scholar working on Pediatrics, Perinatology and Child Health, Rheumatology and Psychiatry and Mental health. According to data from OpenAlex, Benjamin Duncan has authored 23 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pediatrics, Perinatology and Child Health, 5 papers in Rheumatology and 5 papers in Psychiatry and Mental health. Recurrent topics in Benjamin Duncan's work include Rheumatoid Arthritis Research and Therapies (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Inflammatory Bowel Disease (4 papers). Benjamin Duncan is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Inflammatory Bowel Disease (4 papers). Benjamin Duncan collaborates with scholars based in United States, Canada and Belgium. Benjamin Duncan's co-authors include Vallerie V. McLaughlin, Ivan M. Robbins, Ronald J. Oudiz, Diane Zwicke, Shelley Shapiro, Lyn R. Frumkin, David Langleben, Adaani Frost, Evelyn M. Horn and Robyn J. Barst and has published in prestigious journals such as Journal of the American Chemical Society, American Journal of Respiratory and Critical Care Medicine and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Benjamin Duncan

21 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sitaxsentan Therapy for Pulmonary Arterial Hypertension

2003 540 citations Robyn J. Barst, David Langleben et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Duncan United States	13	511	420	263	237	230	23	1.4k
Ulrich Neudorf Germany	22	319 0.6×	385 0.9×	208 0.8×	75 0.3×	48 0.2×	75	1.4k
Alan Gray Saudi Arabia	21	415 0.8×	89 0.2×	228 0.9×	53 0.2×	20 0.1×	46	1.2k
Elliott C. Lasser United States	21	259 0.5×	81 0.2×	227 0.9×	58 0.2×	35 0.2×	87	1.2k
Urs Benck Germany	16	216 0.4×	95 0.2×	349 1.3×	37 0.2×	71 0.3×	42	1.4k
Kelly W. Merriman United States	16	715 1.4×	77 0.2×	505 1.9×	80 0.3×	57 0.2×	41	1.3k
Carlo V. Feo Italy	29	717 1.4×	280 0.7×	1.3k 4.8×	117 0.5×	24 0.1×	130	2.6k
Connie Chen Taiwan	13	144 0.3×	93 0.2×	259 1.0×	60 0.3×	17 0.1×	28	992
Sanjeev Aggarwal United States	27	862 1.7×	1.2k 2.8×	708 2.7×	229 1.0×	26 0.1×	157	2.2k
Werner A. Bleyer United States	15	312 0.6×	55 0.1×	113 0.4×	218 0.9×	59 0.3×	17	1.1k
Martin Kirschstein Germany	13	190 0.4×	330 0.8×	147 0.6×	206 0.9×	11 0.0×	28	1.0k

Countries citing papers authored by Benjamin Duncan

Since Specialization

Citations

This map shows the geographic impact of Benjamin Duncan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Duncan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Duncan more than expected).

Fields of papers citing papers by Benjamin Duncan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Duncan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Duncan. The network helps show where Benjamin Duncan may publish in the future.

Co-authorship network of co-authors of Benjamin Duncan

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Duncan. A scholar is included among the top collaborators of Benjamin Duncan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Duncan. Benjamin Duncan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Vermeire, Séverine, Jean–Frédéric Colombel, Silvio Danese, et al.. (2025). Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease. Journal of Crohn s and Colitis. 20(1).

2.

Loftus, Edward V., Geert D’Haens, Édouard Louis, et al.. (2025). Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: 2-year results from the U-ENDURE Long-Term Extension study. Journal of Crohn s and Colitis. 19(8). 1 indexed citations

3.

D’Haens, Geert, Édouard Louis, Edward V. Loftus, et al.. (2024). OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extension. Journal of Crohn s and Colitis. 18(Supplement_1). i17–i18. 2 indexed citations

4.

Panaccione, Remo, Julián Panés, Laurent Peyrin‐Biroulet, et al.. (2023). S1193 Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease. The American Journal of Gastroenterology. 118(10S). S909–S910. 1 indexed citations

5.

Karothu, Durga Prasad, Karthik Sambath, Stefan Schramm, et al.. (2020). Cracking under Internal Pressure: Photodynamic Behavior of Vinyl Azide Crystals through N₂ Release. Journal of the American Chemical Society. 142(43). 18565–18575. 33 indexed citations

6.

Weinblatt, Michael E., Roy Fleischmann, Ronald van Vollenhoven, et al.. (2015). Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research & Therapy. 17(1). 325–325. 12 indexed citations

7.

Pope, Janet, Clifton O. Bingham, Roy Fleischmann, et al.. (2015). Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. Arthritis Research & Therapy. 17(1). 343–343. 12 indexed citations

8.

Genovese, Mark C., Roy Fleischmann, Daniel E. Furst, et al.. (2014). Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases. 73(9). 1607–1615. 117 indexed citations

9.

Weinblatt, M., Roy Fleischmann, T. Huizinga, et al.. (2012). Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Lara D. Veeken. 51(12). 2204–2214. 99 indexed citations

10.

Trinka, Eugen, Anthony G Marson, Wim Van Paesschen, et al.. (2012). KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Journal of Neurology Neurosurgery & Psychiatry. 84(10). 1138–1147. 90 indexed citations

11.

Weinblatt, M., R Fleischmann, Ronald van Vollenhoven, et al.. (2011). Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study. Data Archiving and Networked Services (DANS). 63(10). 2 indexed citations

12.

Pope, Janet, R. Fleischmann, Maxime Dougados, et al.. (2011). PMS61 Rapid Reductions in Fatigue and Sleep Problems and Correlation with Improvements in Patient-Reported Outcomes in Patients with Active RA Treated with Certolizumab Pegol in the realistic 12-Week Phase IIIB Randomised Controlled Study. Value in Health. 14(7). A313–A313. 3 indexed citations

13.

Piña-Garza, J. Eric, et al.. (2010). Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: Subpopulation analysis of a prospective, open-label extension study of up to 48 weeks. Clinical Therapeutics. 32(11). 1935–1950. 15 indexed citations

14.

Piña-Garza, J. Eric, et al.. (2009). Adjunctive levetiracetam in infants and young children with refractory partial‐onset seizures. Epilepsia. 50(5). 1141–1149. 96 indexed citations

15.

Barst, Robyn J., David Langleben, Adaani Frost, et al.. (2003). Sitaxsentan Therapy for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 169(4). 441–447. 540 indexed citations breakdown →

16.

Chen, Chao, et al.. (1999). Pharmacokinetics of Lamotrigine in Children in the Absence of other Antiepileptic Drugs. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 19(4). 437–441. 42 indexed citations

17.

Moore, Katy H. P., et al.. (1999). Lamivudine/Zidovudine as a Combined Formulation Tablet: Bioequivalence Compared with Lamivudine and Zidovudine Administered Concurrently and the Effect of Food on Absorption. The Journal of Clinical Pharmacology. 39(6). 593–605. 41 indexed citations

18.

Kustra, Robert P., Brian Corrigan, John A. Dunn, Benjamin Duncan, & Poe‐Hirr Hsyu. (1999). Lack of Effect of Cimetidine on the Pharmacokinetics of Sustained‐Release Bupropion. The Journal of Clinical Pharmacology. 39(11). 1184–1188. 15 indexed citations

19.

Fortney, Jennifer T., Tong J. Gan, Bernard V. Wetchler, et al.. (1998). A Comparison of the Efficacy, Safety, and Patient Satisfaction of Ondansetron Versus Droperidol as Antiemetics for Elective Outpatient Surgical Procedures. Anesthesia & Analgesia. 86(4). 731–738. 146 indexed citations

20.

Fortney, Jennifer T., Tong J. Gan, Bernard V. Wetchler, et al.. (1998). A Comparison of the Efficacy, Safety, and Patient Satisfaction of Ondansetron Versus Droperidol as Antiemetics for Elective Outpatient Surgical Procedures. Anesthesia & Analgesia. 86(4). 731–738. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact